Brexpiprazole steers brain chemical signals rather than simply switching them off
In short: Brexpiprazole is an atypical antipsychotic taken as a daily tablet. It adjusts how certain brain messengers respond instead of blocking them outright. Doctors prescribe it for schizophrenia, for depression alongside another antidepressant, and for agitation linked to Alzheimer's dementia. Its warnings are serious, so the full picture matters before drawing conclusions.
Brexpiprazole belongs to a group of medicines called atypical antipsychotics. According to the U.S. drug information service MedlinePlus, its effect is to alter how some natural chemicals in the brain behave. It comes as a tablet taken once a day, with or without food, ideally at the same time each day. Doctors often begin with a low dose and increase it gradually, depending on how well it works and which side effects appear. It manages symptoms but does not cure the underlying illness, which is why patients are advised to continue it and not to stop without medical guidance.
The mechanism is more specific than the broad label suggests. The reference encyclopedia describes brexpiprazole as a partial agonist at dopamine D2 and D3 receptors and at the serotonin 5-HT1A receptor, while also blocking the serotonin 5-HT2A receptor. It is a less stimulating dopamine partial agonist than its predecessor aripiprazole, which may lower the risk of restlessness. Otsuka and Lundbeck developed it, and it received U.S. approval in July 2015.
The safety information is serious and specific. MedlinePlus warns that older adults with dementia may face a higher chance of death when treated with antipsychotics, and that the FDA has not approved brexpiprazole for psychosis without agitation in older adults with Alzheimer's-related dementia. Young people taking antidepressants can carry a greater risk of suicidal thoughts, particularly early in treatment or after a dose change. Patients are also cautioned about raised blood sugar, which can progress to ketoacidosis, and about dizziness on standing quickly. The suicide evidence is still debated. A systematic review and meta-analysis of dopamine partial agonist antipsychotics found no significant change in suicide risk versus placebo in randomized trials, while open-label extension studies showed a signal that the authors say needs cautious interpretation and replication.
A 12-month real-world study of 243 patients with schizophrenia compared brexpiprazole with aripiprazole. Its authors reported that brexpiprazole was superior for patients who also had a substance use disorder, and they describe it as a promising option for these dual-diagnosis patients. That is an encouraging result from one observational study, not a settled verdict, and it should be weighed alongside the broader safety warnings.
Opens the Intellect+ feed with this card first. Swipe up for the next one.
Sources
- Summary by Intellect · source: Brexpiprazole: MedlinePlus Drug Information
- Also: Brexpiprazole
- Also: Brexpiprazole vs. Aripiprazole in Patients with Schizophrenia with or Without Comorbid Substance Use Disorder: A 12-Month Real-World Naturalistic Study of Efficacy.
- Also: Effect of dopamine partial agonist antipsychotics on suicide risk in persons with schizophrenia and schizoaffective disorders: A systematic review and meta-analysis.
To cite this card, link to https://intellectplus.co.uk/app/health-brexpiprazole.
How we source, check and correct cards: Editorial standards.
General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.
Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?
Related
More in Anatomy and morphology · More in Health · Latest · A–Z · All topics